RVLP Key Statistics, Chart & Performance
The current stock price of RVLP is 0.0282 USD. In the past month the price decreased by -71.8%. In the past year, price decreased by -98.37%.
RVLP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About RVLP
Company Profile
RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey and currently employs 125 full-time employees. The company went IPO on 2018-10-12. The firm is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The firm is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.
Company Info
RVL PHARMACEUTICALS PLC
400 Crossing Boulevard
Bridgewater NEW JERSEY US
Employees: 125
Phone: 19088091300.0
RVL PHARMACEUTICALS PLC / RVLP FAQ
What does RVLP do?
RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey and currently employs 125 full-time employees. The company went IPO on 2018-10-12. The firm is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The firm is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.
Can you provide the latest stock price for RVL PHARMACEUTICALS PLC?
The current stock price of RVLP is 0.0282 USD. The price decreased by -32.05% in the last trading session.
Does RVLP stock pay dividends?
RVLP does not pay a dividend.
How is the ChartMill rating for RVL PHARMACEUTICALS PLC?
RVLP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about RVL PHARMACEUTICALS PLC (RVLP) stock?
9 analysts have analysed RVLP and the average price target is 3.21 USD. This implies a price increase of 11293.62% is expected in the next year compared to the current price of 0.0282.
Is RVL PHARMACEUTICALS PLC (RVLP) expected to grow?
The Revenue of RVL PHARMACEUTICALS PLC (RVLP) is expected to decline by -28.9% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for RVL PHARMACEUTICALS PLC?
RVL PHARMACEUTICALS PLC (RVLP) has a market capitalization of 3.14M USD. This makes RVLP a Nano Cap stock.
RVLP Technical Analysis
RVLP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RVLP. RVLP has a bad profitability rating. Also its financial health evaluation is rather negative.
RVLP Financial Highlights
Over the last trailing twelve months RVLP reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 27.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.93% | ||
| ROE | -418.14% | ||
| Debt/Equity | 0 |
RVLP Forecast & Estimates
9 analysts have analysed RVLP and the average price target is 3.21 USD. This implies a price increase of 11293.62% is expected in the next year compared to the current price of 0.0282.
For the next year, analysts expect an EPS growth of 27.9% and a revenue growth -28.9% for RVLP